Deconstructing the antiviral neutralizing-Antibody response: Implications for vaccine development and immunity

Microbiology and Molecular Biology Reviews

Volumn 80, Issue 4, 2016, Pages 989-1010

  Vanblargan, Laura A ^a   Goo, Leslie ^a   Pierson, Theodore C ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; POLYCLONAL ANTIBODY; VIRUS VACCINE; VIRUS ANTIBODY;

ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; FLAVIVIRUS; FLAVIVIRUS INFECTION; GERMINAL CENTER; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNITY; NONHUMAN; VACCINATION; VIRUS INFECTION; FLAVIVIRUS INFECTIONS; HIV INFECTIONS; HUMAN; IMMUNE EVASION; IMMUNOLOGY; VIROLOGY;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; FLAVIVIRUS; FLAVIVIRUS INFECTIONS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNE EVASION; IMMUNITY, HUMORAL; VIRAL VACCINES;

EID: 84995684215     PISSN: 10922172     EISSN: 10985557     Source Type: Journal    
DOI: 10.1128/MMBR.00024-15     Document Type: Article

References (298)

1. Schroeder HW Jr, Cavacini L. 2010. Structure and function of immunoglobulins. J Allergy Clin Immunol 125:S41-S52. http://dx.doi.org/10.1016/j.jaci.2009.09.046.
2. Burton DR, Saphire EO, Parren PW. 2001. A model for neutralization of viruses based on antibody coating of the virion surface. Curr Top Microbiol Immunol 260:109-143.
3. Plotkin SA. 2010. Correlates of protection induced by vaccination. Clin Vaccine Immunol 17:1055-1065. http://dx.doi.org/10.1128/CVI.00131-10.
4. Burton DR, Poignard P, Stanfield RL, Wilson IA. 2012. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science 337:183-186. http://dx.doi.org/10.1126/science.1225416.
5. Doria-Rose NA, Joyce MG. 2015. Strategies to guide the antibody affinity maturation process. Curr Opin Virol 11:137-147. http://dx.doi.org/10.1016/j.coviro.2015.04.002.
6. Wibmer CK, Moore PL, Morris L. 2015. HIV broadly neutralizing antibody targets. Curr Opin HIV AIDS 10:135-143. http://dx.doi.org/10.1097/COH.0000000000000153.
7. Correia BE, Bates JT, Loomis RJ, Baneyx G, Carrico C, Jardine JG, Rupert P, Correnti C, Kalyuzhniy O, Vittal V, Connell MJ, Stevens E, Schroeter A, Chen M, Macpherson S, Serra AM, Adachi Y, Holmes MA, Li Y, Klevit RE, Graham BS, Wyatt RT, Baker D, Strong RK, Crowe JE Jr, Johnson PR, Schief WR. 2014. Proof of principle for epitope-focused vaccine design. Nature 507:201-206. http://dx.doi.org/10.1038/nature12966.
8. Corti D, Lanzavecchia A. 2013. Broadly neutralizing antiviral antibodies. Annu Rev Immunol 31:705-742. http://dx.doi.org/10.1146/annurev-immunol-032712-095916.
9. Diamond MS, Pierson TC, Fremont DH. 2008. The structural immunology of antibody protection against West Nile virus. Immunol Rev 225:212-225. http://dx.doi.org/10.1111/j.1600-065X.2008.00676.x.
10. West AP Jr, Scharf L, Scheid JF, Klein F, Bjorkman PJ, Nussenzweig MC. 2014. Structural insights on the role of antibodies in HIV-1 vaccine and therapy. Cell 156:633-648. http://dx.doi.org/10.1016/j.cell.2014.01.052.
11. Cashman SB, Marsden BD, Dustin LB. 2014. The humoral immune response to HCV: understanding is key to vaccine development. Front Immunol 5:550. http://dx.doi.org/10.3389/fimmu.2014.00550.
12. Mallery DL, McEwan WA, Bidgood SR, Towers GJ, Johnson CM, James LC. 2010. Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21). Proc Natl Acad Sci U S A 107: 19985-19990. http://dx.doi.org/10.1073/pnas.1014074107.
13. Mouquet H. 2014. Antibody B cell responses in HIV-1 infection. Trends Immunol 35:549-561. http://dx.doi.org/10.1016/j.it.2014.08.007.
14. Kwong PD, Mascola JR, Nabel GJ. 2013. Broadly neutralizing antibodies and the search for an HIV-1 vaccine: The end of the beginning. Nat Rev Immunol 13:693-701. http://dx.doi.org/10.1038/nri3516.
15. Overbaugh J, Morris L. 2012. The antibody response against HIV-1. Cold Spring Harb Perspect Med 2:a007039. http://dx.doi.org/10.1101/cshperspect.a007039.
16. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, Myers MF, George DB, Jaenisch T, Wint GR, Simmons CP, Scott TW, Farrar JJ, Hay SI. 7 April 2013. The global distribution and burden of dengue. Nature http://dx.doi.org/10.1038/nature12060.
17. Wikan N, Smith DR. 2016. Zika virus: history of a newly emerging arbovirus. Lancet Infect Dis 16:e119-e126. http://dx.doi.org/10.1016/S1473-3099(16)30010-X.
18. Roehrig JT. 2013. West Nile virus in the United States-A historical perspective. Viruses 5:3088-3108. http://dx.doi.org/10.3390/v5123088.
19. Calisher CH, Gould EA. 2003. Taxonomy of the virus family Flaviviridae. Adv Virus Res 59:1-19. http://dx.doi.org/10.1016/S0065-3527(03)59001-7.
20. Kuno G, Chang GJ, Tsuchiya KR, Karabatsos N, Cropp CB. 1998. Phylogeny of the genus Flavivirus. J Virol 72:73-83.
21. King AMQ, Adams MJ, Carstens EB, Lefkowitz EJ. 2012. Virus taxonomy. Classification and nomenclature of viruses. Ninth report of the International Committee on Taxonomy of Viruses. Elsevier Academic Press, San Diego, CA.
22. Mackenzie JM, Westaway EG. 2001. Assembly and maturation of the flavivirus Kunjin virus appear to occur in the rough endoplasmic reticulum and along the secretory pathway, respectively. J Virol 75:10787- 10799. http://dx.doi.org/10.1128/JVI.75.22.10787-10799.2001.
23. Lorenz IC, Kartenbeck J, Mezzacasa A, Allison SL, Heinz FX, Helenius A. 2003. Intracellular assembly and secretion of recombinant subviral particles from tick-borne encephalitis virus. J Virol 77:4370-4382. http://dx.doi.org/10.1128/JVI.77.7.4370-4382.2003.
24. Lorenz IC, Allison SL, Heinz FX, Helenius A. 2002. Folding and dimerization of tick-borne encephalitis virus envelope proteins prM and E in the endoplasmic reticulum. J Virol 76:5480-5491. http://dx.doi.org/10.1128/JVI.76.11.5480-5491.2002.
25. Li L, Lok SM, Yu IM, Zhang Y, Kuhn RJ, Chen J, Rossmann MG. 2008. The flavivirus precursor membrane-envelope protein complex: structure and maturation. Science 319:1830-1834. http://dx.doi.org/10.1126/science.1153263.
26. Zhang Y, Kaufmann B, Chipman PR, Kuhn RJ, Rossmann MG. 2007. Structure of immature West Nile virus. J Virol 81:6141-6145. http://dx.doi.org/10.1128/JVI.00037-07.
27. Zhang Y, Corver J, Chipman PR, Zhang W, Pletnev SV, Sedlak D, Baker TS, Strauss JH, Kuhn RJ, Rossmann MG. 2003. Structures of immature flavivirus particles. EMBO J 22:2604-2613. http://dx.doi.org/10.1093/emboj/cdg270.
28. Allison SL, Stadler K, Mandl CW, Kunz C, Heinz FX. 1995. Synthesis and secretion of recombinant tick-borne encephalitis virus protein E in soluble and particulate form. J Virol 69:5816-5820.
29. Heinz FX, Stiasny K, Puschner-Auer G, Holzmann H, Allison SL, Mandl CW, Kunz C. 1994. Structural changes and functional control of the tick-borne encephalitis virus glycoprotein E by the heterodimericassociation with protein prM. Virology 198:109-117. http://dx.doi.org/10.1006/viro.1994.1013.
30. Elshuber S, Allison SL, Heinz FX, Mandl CW. 2003. Cleavage of protein prM is necessary for infection of BHK-21 cells by tick-borne encephalitis virus. J Gen Virol 84:183-191. http://dx.doi.org/10.1099/vir.0.18723-0.
31. Stadler K, Allison SL, Schalich J, Heinz FX. 1997. Proteolytic activation of tick-borne encephalitis virus by furin. J Virol 71:8475-8481.
32. Yu IM, Zhang W, Holdaway HA, Li L, Kostyuchenko VA, Chipman PR, Kuhn RJ, Rossmann MG, Chen J. 2008. Structure of the immature dengue virus at low pH primes proteolytic maturation. Science 319: 1834-1837. http://dx.doi.org/10.1126/science.1153264.
33. Mukhopadhyay S, Kim BS, Chipman PR, Rossmann MG, Kuhn RJ. 2003. Structure of West Nile virus. Science 302:248. http://dx.doi.org/10.1126/science.1089316.
34. Kuhn RJ, Zhang W, Rossmann MG, Pletnev SV, Corver J, Lenches E, Jones CT, Mukhopadhyay S, Chipman PR, Strauss EG, Baker TS, Strauss JH. 2002. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 108:717-725. http://dx.doi.org/10.1016/S0092-8674(02)00660-8.
35. Zhang X, Sheng J, Plevka P, Kuhn RJ, Diamond MS, Rossmann MG. 8 April 2013. Dengue structure differs at the temperatures of its human and mosquito hosts. Proc Natl Acad Sci U S A http://dx.doi.org/10.1073/pnas.1304300110.
36. Sirohi D, Chen Z, Sun L, Klose T, Pierson TC, Rossmann MG, Kuhn RJ. 2016. The 3.8 A resolution cryo-EM structure of Zika virus. Science 352:467-470. http://dx.doi.org/10.1126/science.aaf5316.
37. Kostyuchenko VA, Lim EX, Zhang S, Fibriansah G, Ng TS, Ooi JS, Shi J, Lok SM. 2016. Structure of the thermally stable Zika virus. Nature 533:425-428. http://dx.doi.org/10.1038/nature17994.
38. Zhang X, Ge P, Yu X, Brannan JM, Bi G, Zhang Q, Schein S, Zhou ZH. 2013. Cryo-EM structure of the mature dengue virus at 3.5-A resolution. Nat Struct Mol Biol 20:105-110. http://dx.doi.org/10.1038/nsmb.2463.
39. Pierson TC, Diamond MS. 2012. Degrees of maturity: The complex structure and biology of flaviviruses. Curr Opin Virol 2:168-175. http://dx.doi.org/10.1016/j.coviro.2012.02.011.
40. Davis CW, Nguyen HY, Hanna SL, Sanchez MD, Doms RW, Pierson TC. 2006. West Nile virus discriminates between DC-SIGN and DCSIGNR for cellular attachment and infection. J Virol 80:1290-1301. http://dx.doi.org/10.1128/JVI.80.3.1290-1301.2006.
41. Nelson S, Jost CA, Xu Q, Ess J, Martin JE, Oliphant T, Whitehead SS, Durbin AP, Graham BS, Diamond MS, Pierson TC. 2008. Maturation of West Nile virus modulates sensitivity to antibodymediated neutralization. PLoS Pathog 4:e1000060. http://dx.doi.org/10.1371/journal.ppat.1000060.
42. Mukherjee S, Dowd KA, Manhart CJ, Ledgerwood JE, Durbin AP, Whitehead SS, Pierson TC. 2014. Mechanism and significance of cell type-dependent neutralization of flaviviruses. J Virol 88:7210-7220. http://dx.doi.org/10.1128/JVI.03690-13.
43. Dowd KA, Mukherjee S, Kuhn RJ, Pierson TC. 2014. Combined effects of the structural heterogeneity and dynamics of flaviviruses on antibody recognition. J Virol 88:11726 -11737. http://dx.doi.org/10.1128/JVI.01140-14.
44. Guirakhoo F, Bolin RA, Roehrig JT. 1992. The Murray Valley encephalitis virus prM protein confers acid resistance to virus particles and alters the expression of epitopes within the R2 domain of E glycoprotein. Virology 191:921-931. http://dx.doi.org/10.1016/0042-6822(92)90267-S.
45. Roehrig JT. 2003. Antigenic structure of flavivirus proteins. Adv Virus Res 59:141-175. http://dx.doi.org/10.1016/S0065-3527(03)59005-4.
46. Rey FA, Heinz FX, Mandl C, Kunz C, Harrison SC. 1995. The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature 375:291-298. http://dx.doi.org/10.1038/375291a0.
47. Mukhopadhyay S, Kuhn RJ, Rossmann MG. 2005. A structural perspective of the flavivirus life cycle. Nat Rev Microbiol 3:13-22. http://dx.doi.org/10.1038/nrmicro1067.
48. Winkler G, Heinz FX, Kunz C. 1987. Studies on the glycosylation of flavivirus E proteins and the role of carbohydrate in antigenic structure. Virology 159:237-243. http://dx.doi.org/10.1016/0042-6822(87)90460-0.
49. Shirato K, Miyoshi H, Goto A, Ako Y, Ueki T, Kariwa H, Takashima I. 2004. Viral envelope protein glycosylation is a molecular determinant of the neuroinvasiveness of the New York strain of West Nile virus. J Gen Virol 85:3637-3645. http://dx.doi.org/10.1099/vir.0.80247-0.
50. Shrestha B, Brien JD, Sukupolvi-Petty S, Austin SK, Edeling MA, Kim T, O'Brien KM, Nelson CA, Johnson S, Fremont DH, Diamond MS. 2010. The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog 6:e1000823. http://dx.doi.org/10.1371/journal.ppat.1000823.
51. Sukupolvi-Petty S, Austin SK, Engle M, Brien JD, Dowd KA, Williams KL, Johnson S, Rico-Hesse R, Harris E, Pierson TC, Fremont DH, Diamond MS. 2010. Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J Virol 84:9227- 9239. http://dx.doi.org/10.1128/JVI.01087-10.
52. Sukupolvi-Petty S, Austin SK, Purtha WE, Oliphant T, Nybakken GE, Schlesinger JJ, Roehrig JT, Gromowski GD, Barrett AD, Fremont DH, Diamond MS. 2007. Type-And subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol 81:12816-12826. http://dx.doi.org/10.1128/JVI.00432-07.
53. Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L, Quyen NT, Sukupolvi-Petty S, Navarro-Sanchez E, Young PR, de Silva AM, Rey FA, Varani L, Whitehead SS, Diamond MS, Harris E, Lanzavecchia A, Sallusto F. 2010. The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 8:271-283. http://dx.doi.org/10.1016/j.chom.2010.08.007.
54. Roehrig JT, Bolin RA, Kelly RG. 1998. Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology 246:317-328. http://dx.doi.org/10.1006/viro.1998.9200.
55. Crill WD, Roehrig JT. 2001. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J Virol 75:7769-7773. http://dx.doi.org/10.1128/JVI.75.16.7769-7773.2001.
56. Crill WD, Chang GJ. 2004. Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes. J Virol 78:13975- 13986. http://dx.doi.org/10.1128/JVI.78.24.13975-13986.2004.
57. Stiasny K, Kiermayr S, Holzmann H, Heinz FX. 2006. Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites. J Virol 80:9557-9568. http://dx.doi.org/10.1128/JVI.00080-06.
58. Stiasny K, Brandler S, Kossl C, Heinz FX. 2007. Probing the flavivirus membrane fusion mechanism by using monoclonal antibodies. J Virol 81:11526-11531. http://dx.doi.org/10.1128/JVI.01041-07.
59. Vogt MR, Moesker B, Goudsmit J, Jongeneelen M, Austin SK, Oliphant T, Nelson S, Pierson TC, Wilschut J, Throsby M, Diamond MS. 2009. Human monoclonal antibodies against West Nile virus induced by natural infection neutralize at a postattachment step. J Virol 83:6494- 6507. http://dx.doi.org/10.1128/JVI.00286-09.
60. de Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP, Wahala WM, White LJ, Diamond MS, Baric RS, Crowe JE Jr, de Silva AM. 2012. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci U S A 109:7439- 7444. http://dx.doi.org/10.1073/pnas.1200566109.
61. Teoh EP, Kukkaro P, Teo EW, Lim AP, Tan TT, Yip A, Schul W, Aung M, Kostyuchenko VA, Leo YS, Chan SH, Smith KG, Chan AH, Zou G, Ooi EE, Kemeny DM, Tan GK, Ng JK, Ng ML, Alonso S, Fisher D, Shi PY, Hanson BJ, Lok SM, MacAry PA. 2012. The structural basis for serotype-specific neutralization of dengue virus by a human antibody. Sci Transl Med 4:139-83. http://dx.doi.org/10.1126/scitranslmed.3003888.
62. de Alwis R, Beltramello M, Messer WB, Sukupolvi-Petty S, Wahala WM, Kraus A, Olivarez NP, Pham Q, Brien JD, Tsai WY, Wang WK, Halstead S, Kliks S, Diamond MS, Baric R, Lanzavecchia A, Sallusto F, de Silva AM. 2011. In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLoS Negl Trop Dis 5:e1188. http://dx.doi.org/10.1371/journal.pntd.0001188.
63. Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, Limpitikul W, Puttikhunt C, Edwards C, Duangchinda T, Supasa S, Chawansuntati K, Malasit P, Mongkolsapaya J, Screaton G. 2010. Cross-reacting antibodies enhance dengue virus infection in humans. Science 328:745-748. http://dx.doi.org/10.1126/science.1185181.
64. Smith SA, Zhou Y, Olivarez NP, Broadwater AH, de Silva AM, Crowe JE Jr. 2012. Persistence of circulating memory B cell clones with potential for dengue virus disease enhancement for decades following infection. J Virol 86:2665-2675. http://dx.doi.org/10.1128/JVI.06335-11.
65. Stiasny K, Heinz FX. 2006. Flavivirus membrane fusion. J Gen Virol 87:2755-2766. http://dx.doi.org/10.1099/vir.0.82210-0.
66. Corver J, Ortiz A, Allison SL, Schalich J, Heinz FX, Wilschut J. 2000. Membrane fusion activity of tick-borne encephalitis virus and recombinant subviral particles in a liposomal model system. Virology 269:37-46. http://dx.doi.org/10.1006/viro.1999.0172.
67. van der Schaar HM, Rust MJ, Chen C, van der Ende-Metselaar H, Wilschut J, Zhuang X, Smit JM. 2008. Dissecting the cell entry pathway of dengue virus by single-particle tracking in living cells. PLoS Pathog 4:e1000244. http://dx.doi.org/10.1371/journal.ppat.1000244.
68. Zaitseva E, Yang ST, Melikov K, Pourmal S, Chernomordik LV. 2010. Dengue virus ensures its fusion in late endosomes using compartmentspecific lipids. PLoS Pathog 6:e1001131. http://dx.doi.org/10.1371/journal.ppat.1001131.
69. Chen Y, Maguire T, Hileman RE, Fromm JR, Esko JD, Linhardt RJ, Marks RM. 1997. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat Med 3:866-871. http://dx.doi.org/10.1038/nm0897-866.
70. Meertens L, Carnec X, Lecoin MP, Ramdasi R, Guivel-Benhassine F, Lew E, Lemke G, Schwartz O, Amara A. 2012. The TIM and TAM families of phosphatidylserine receptors mediate dengue virus entry. Cell Host Microbe 12:544-557. http://dx.doi.org/10.1016/j.chom.2012.08.009.
71. Miller JL, de Wet BJ, Martinez-Pomares L, Radcliffe CM, Dwek RA, Rudd PM, Gordon S. 2008. The mannose receptor mediates dengue virus infection of macrophages. PLoS Pathog 4:e17. http://dx.doi.org/10.1371/journal.ppat.0040017.
72. Tassaneetrithep B, Burgess TH, Granelli-Piperno A, Trumpfheller C, Finke J, Sun W, Eller MA, Pattanapanyasat K, Sarasombath S, Birx DL, Steinman RM, Schlesinger S, Marovich MA. 2003. DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. J Exp Med 197:823-829. http://dx.doi.org/10.1084/jem.20021840.
73. Navarro-Sanchez E, Altmeyer R, Amara A, Schwartz O, Fieschi F, Virelizier JL, Arenzana-Seisdedos F, Despres P. 2003. Dendritic-cell-specific ICAM3-grabbing non-integrin is essential for the productive infection of human dendritic cells by mosquito-cell-derived dengue viruses. EMBORep 4:723-728. http://dx.doi.org/10.1038/sj.embor.embor866.
74. Carnec X, Meertens L, Dejarnac O, Perera-Lecoin M, Hafirassou ML, Kitaura J, Ramdasi R, Schwartz O, Amara A. 2016. The phosphatidylserine and phosphatidylethanolamine receptor CD300a binds dengue virus and enhances infection. J Virol 90:92-102. http://dx.doi.org/10.1128/JVI.01849-15.
75. Hamel R, Dejarnac O, Wichit S, Ekchariyawat P, Neyret A, Luplertlop N, Perera-Lecoin M, Surasombatpattana P, Talignani L, Thomas F, Cao-Lormeau VM, Choumet V, Briant L, Despres P, Amara A, Yssel H, Misse D. 2015. Biology of Zika virus infection in human skin cells. J Virol 89:8880-8896. http://dx.doi.org/10.1128/JVI.00354-15.
76. Gollins SW, Porterfield JS. 1986. pH-dependent fusion between the flavivirus West Nile and liposomal model membranes. J Gen Virol 67(Part 1):157-166.
77. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-126. http://dx.doi.org/10.1038/373123a0.
78. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH, Saag MS, Shaw GM. 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117-122. http://dx.doi.org/10.1038/373117a0.
79. Mansky LM, Temin HM. 1995. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 69:5087-5094.
80. Hu WS, Hughes SH. 2012. HIV-1 reverse transcription. Cold Spring Harb Perspect Med 2:a006882. http://dx.doi.org/10.1101/cshperspect.a006882.
81. Sharp PM, Hahn BH. 2011. Origins of HIV and the AIDS pandemic. Cold Spring Harb Perspect Med 1:a006841. http://dx.doi.org/10.1101/cshperspect.a006841.
82. Robertson DL, Anderson JP, Bradac JA, Carr JK, Foley B, Funkhouser RK, Gao F, Hahn BH, Kalish ML, Kuiken C, Learn GH, Leitner T, McCutchan F, Osmanov S, Peeters M, Pieniazek D, Salminen M, Sharp PM, Wolinsky S, Korber B. 2000. HIV-1 nomenclature proposal. Science 288:55-56.
83. Hemelaar J. 2013. Implications of HIV diversity for the HIV-1 pandemic. J Infect 66:391-400. http://dx.doi.org/10.1016/j.jinf.2012.10.026.
84. Gaschen B, Taylor J, Yusim K, Foley B, Gao F, Lang D, Novitsky V, Haynes B, Hahn BH, Bhattacharya T, Korber B. 2002. Diversity considerations in HIV-1 vaccine selection. Science 296:2354-2360. http://dx.doi.org/10.1126/science.1070441.
85. Korber B, Gaschen B, Yusim K, Thakallapally R, Kesmir C, Detours V. 2001. Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull 58:19-42. http://dx.doi.org/10.1093/bmb/58.1.19.
86. Zhu P, Liu J, Bess J Jr, Chertova E, Lifson JD, Grise H, Ofek GA, Taylor KA, Roux KH. 2006. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 441:847-852. http://dx.doi.org/10.1038/nature04817.
87. Chojnacki J, Staudt T, Glass B, Bingen P, Engelhardt J, Anders M, Schneider J, Muller B, Hell SW, Krausslich HG. 2012. Maturationdependent HIV-1 surface protein redistribution revealed by fluorescence nanoscopy. Science 338:524-528. http://dx.doi.org/10.1126/science.1226359.
88. Brandenberg OF, Magnus C, Rusert P, Regoes RR, Trkola A. 2015. Different infectivity of HIV-1 strains is linked to number of envelope trimers required for entry. PLoS Pathog 11:e1004595. http://dx.doi.org/10.1371/journal.ppat.1004595.
89. Tedbury PR, Freed EO. 2014. The role of matrix in HIV-1 envelope glycoprotein incorporation. Trends Microbiol 22:372-378. http://dx.doi.org/10.1016/j.tim.2014.04.012.
90. Postler TS, Desrosiers RC. 2013. The tale of the long tail: The cytoplasmic domain of HIV-1 gp41. J Virol 87:2-15. http://dx.doi.org/10.1128/JVI.02053-12.
91. Ott DE. 2008. Cellular proteins detected in HIV-1. Rev Med Virol 18: 159-175. http://dx.doi.org/10.1002/rmv.570.
92. Freed EO, Martin MA. 1995. The role of human immunodeficiency virus type 1 envelope glycoproteins in virus infection. J Biol Chem 270: 23883-23886. http://dx.doi.org/10.1074/jbc.270.41.23883.
93. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. 1998. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393: 648-659. http://dx.doi.org/10.1038/31405.
94. Pancera M, Shahzad-Ul-Hussan S, Doria-Rose NA, McLellan JS, Bailer RT, Dai K, Loesgen S, Louder MK, Staupe RP, Yang Y, Zhang B, Parks R, Eudailey J, Lloyd KE, Blinn J, Alam SM, Haynes BF, Amin MN, Wang LX, Burton DR, Koff WC, Nabel GJ, Mascola JR, Bewley CA, Kwong PD. 2013. Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16. Nat Struct Mol Biol 20:804-813. http://dx.doi.org/10.1038/nsmb.2600.
95. Julien JP, Cupo A, Sok D, Stanfield RL, Lyumkis D, Deller MC, Klasse PJ, Burton DR, Sanders RW, Moore JP, Ward AB, Wilson IA. 2013. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 342:1477-1483. http://dx.doi.org/10.1126/science.1245625.
96. Lyumkis D, Julien JP, de Val N, Cupo A, Potter CS, Klasse PJ, Burton DR, Sanders RW, Moore JP, Carragher B, Wilson IA, Ward AB. 2013. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science 342:1484-1490. http://dx.doi.org/10.1126/science.1245627.
97. Lee JH, Ozorowski G, Ward AB. 2016. Cryo-EM structure of a native, fully glycosylated, cleaved HIV-1 envelope trimer. Science 351:1043- 1048. http://dx.doi.org/10.1126/science.aad2450.
98. Stewart-Jones GB, Soto C, Lemmin T, Chuang GY, Druz A, Kong R, Thomas PV, Wagh K, Zhou T, Behrens AJ, Bylund T, Choi CW, Davison JR, Georgiev IS, Joyce MG, Kwon YD, Pancera M, Taft J, Yang Y, Zhang B, Shivatare SS, Shivatare VS, Lee CC, Wu CY, Bewley CA, Burton DR, Koff WC, Connors M, Crispin M, Baxa U, Korber BT, Wong CH, Mascola JR, Kwong PD. 2016. Trimeric HIV-1-Env structures define glycan shields from clades A, B, and G. Cell 165:813-826. http://dx.doi.org/10.1016/j.cell.2016.04.010.
99. Pancera M, Zhou T, Druz A, Georgiev IS, Soto C, Gorman J, Huang J, Acharya P, Chuang GY, Ofek G, Stewart-Jones GB, Stuckey J, Bailer RT, Joyce MG, Louder MK, Tumba N, Yang Y, Zhang B, Cohen MS, Haynes BF, Mascola JR, Morris L, Munro JB, Blanchard SC, Mothes W, Connors M, Kwong PD. 2014. Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature 514:455-461. http://dx.doi.org/10.1038/nature13808.
100. Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, Hendrickson WA, Sodroski JG. 1998. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393:705-711. http://dx.doi.org/10.1038/31514.
101. Doores KJ. 2015. The HIV glycan shield as a target for broadly neutralizing antibodies. FEBS J 282:4679-4691. http://dx.doi.org/10.1111/febs.13530.
102. Albert J, Abrahamsson B, Nagy K, Aurelius E, Gaines H, Nystrom G, Fenyo EM. 1990. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS 4:107-112. http://dx.doi.org/10.1097/00002030-199002000-00002.
103. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar- Gonzalez JF, Salazar MG, Kilby JM, Saag MS, Komarova NL, Nowak MA, Hahn BH, Kwong PD, Shaw GM. 2003. Antibody neutralization and escape by HIV-1. Nature 422:307-312. http://dx.doi.org/10.1038/nature01470.
104. Richman DD, Wrin T, Little SJ, Petropoulos CJ. 2003. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 100:4144-4149. http://dx.doi.org/10.1073/pnas.0630530100.
105. Rong R, Li B, Lynch RM, Haaland RE, Murphy MK, Mulenga J, Allen SA, Pinter A, Shaw GM, Hunter E, Robinson JE, Gnanakaran S, Derdeyn CA. 2009. Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways. PLoS Pathog 5:e1000594. http://dx.doi.org/10.1371/journal.ppat.1000594.
106. Moore PL, Ranchobe N, Lambson BE, Gray ES, Cave E, Abrahams MR, Bandawe G, Mlisana K, Abdool Karim SS, Williamson C, Morris L, CAPRISA 002 Study, NIAID Center for HIV/AIDS Vaccine Immunology. 2009. Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. PLoS Pathog 5:e1000598. http://dx.doi.org/10.1371/journal.ppat.1000598.
107. Davis KL, Gray ES, Moore PL, Decker JM, Salomon A, Montefiori DC, Graham BS, Keefer MC, Pinter A, Morris L, Hahn BH, Shaw GM. 2009. High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination. Virology 387:414-426. http://dx.doi.org/10.1016/j.virol.2009.02.022.
108. Klein JS, Gnanapragasam PN, Galimidi RP, Foglesong CP, West AP Jr, Bjorkman PJ. 2009. Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10. Proc Natl Acad Sci U S A 106:7385-7390. http://dx.doi.org/10.1073/pnas.0811427106.
109. Huang J, Ofek G, Laub L, Louder MK, Doria-Rose NA, Longo NS, Imamichi H, Bailer RT, Chakrabarti B, Sharma SK, Alam SM, Wang T, Yang Y, Zhang B, Migueles SA, Wyatt R, Haynes BF, Kwong PD, Mascola JR, Connors M. 2012. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491:406-412. http://dx.doi.org/10.1038/nature11544.
110. Huang J, Kang BH, Pancera M, Lee JH, Tong T, Feng Y, Imamichi H, Georgiev IS, Chuang GY, Druz A, Doria-Rose NA, Laub L, Sliepen K, van Gils MJ, de la Pena AT, Derking R, Klasse PJ, Migueles SA, Bailer RT, Alam M, Pugach P, Haynes BF, Wyatt RT, Sanders RW, Binley JM, Ward AB, Mascola JR, Kwong PD, Connors M. 2014. Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature 515:138 -142. http://dx.doi.org/10.1038/nature13601.
111. Scharf L, Scheid JF, Lee JH, West AP Jr, Chen C, Gao H, Gnanapragasam PN, Mares R, Seaman MS, Ward AB, Nussenzweig MC, Bjorkman PJ. 2014. Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike. Cell Rep 7:785-795. http://dx.doi.org/10.1016/j.celrep.2014.04.001.
112. Blattner C, Lee JH, Sliepen K, Derking R, Falkowska E, de la Pena AT, Cupo A, Julien JP, van Gils M, Lee PS, Peng W, Paulson JC, Poignard P, Burton DR, Moore JP, Sanders RW, Wilson IA, Ward AB. 2014. Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers. Immunity 40:669- 680. http://dx.doi.org/10.1016/j.immuni.2014.04.008.
113. Falkowska E, Le KM, Ramos A, Doores KJ, Lee JH, Blattner C, Ramirez A, Derking R, van Gils MJ, Liang CH, McBride R, von Bredow B, Shivatare SS, Wu CY, Chan-Hui PY, Liu Y, Feizi T, Zwick MB, Koff WC, Seaman MS, Swiderek K, Moore JP, Evans D, Paulson JC, Wong CH, Ward AB, Wilson IA, Sanders RW, Poignard P, Burton DR. 2014. Broadly neutralizing HIV antibodies define a glycandependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. Immunity 40:657-668. http://dx.doi.org/10.1016/j.immuni.2014.04.009.
114. Kong R, Xu K, Zhou T, Acharya P, Lemmin T, Liu K, Ozorowski G, Soto C, Taft JD, Bailer RT, Cale EM, Chen L, Choi CW, Chuang GY, Doria-Rose NA, Druz A, Georgiev IS, Gorman J, Huang J, Joyce MG, Louder MK, Ma X, McKee K, O'Dell S, Pancera M, Yang Y, Blanchard SC, Mothes W, Burton DR, Koff WC, Connors M, Ward AB, Kwong PD, Mascola JR. 2016. Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody. Science 352:828-833. http://dx.doi.org/10.1126/science.aae0474.
115. Melikyan GB. 2014. HIV entry: A game of hide-And-fuse? Curr Opin Virol 4:1-7. http://dx.doi.org/10.1016/j.coviro.2013.09.004.
116. Munro JB, Gorman J, Ma X, Zhou Z, Arthos J, Burton DR, Koff WC, Courter JR, Smith AB, III, Kwong PD, Blanchard SC, Mothes W. 2014. Conformational dynamics of single HIV-1 envelope trimers on the surface of native virions. Science 346:759-763. http://dx.doi.org/10.1126/science.1254426.
117. Klasse PJ. 2012. The molecular basis of HIV entry. Cell Microbiol 14: 1183-1192. http://dx.doi.org/10.1111/j.1462-5822.2012.01812.x.
118. Sougrat R, Bartesaghi A, Lifson JD, Bennett AE, Bess JW, Zabransky DJ, Subramaniam S. 2007. Electron tomography of the contact between T cells and SIV/HIV-1: implications for viral entry. PLoS Pathog 3:e63. http://dx.doi.org/10.1371/journal.ppat.0030063.
119. Yang X, Kurteva S, Lee S, Sodroski J. 2005. Stoichiometry of antibody neutralization of human immunodeficiency virus type 1. J Virol 79: 3500-3508. http://dx.doi.org/10.1128/JVI.79.6.3500-3508.2005.
120. Magnus C, Rusert P, Bonhoeffer S, Trkola A, Regoes RR. 2009. Estimating the stoichiometry of human immunodeficiency virus entry. J Virol 83:1523-1531. http://dx.doi.org/10.1128/JVI.01764-08.
121. Klasse PJ. 2007. Modeling how many envelope glycoprotein trimers per virion participate in human immunodeficiency virus infectivity and its neutralization by antibody. Virology 369:245-262. http://dx.doi.org/10.1016/j.virol.2007.06.044.
122. Woof JM, Burton DR. 2004. Human antibody-Fc receptor interactions illuminated by crystal structures. Nat Rev Immunol 4:89-99. http://dx.doi.org/10.1038/nri1266.
123. Bergman Y, Cedar H. 2004. A stepwise epigenetic process controls immunoglobulin allelic exclusion. Nat Rev Immunol 4:753-761. http://dx.doi.org/10.1038/nri1458.
124. Chaudhuri J, Alt FW. 2004. Class-switch recombination: interplay of transcription, DNA deamination and DNA repair. Nat Rev Immunol 4:541-552. http://dx.doi.org/10.1038/nri1395.
125. Shlomchik MJ, Weisel F. 2012. Germinal center selection and the development of memory B and plasma cells. Immunol Rev 247:52-63. http://dx.doi.org/10.1111/j.1600-065X.2012.01124.x.
126. Taylor JJ, Pape KA, Jenkins MK. 2012. A germinal centerindependent pathway generates unswitched memory B cells early in the primary response. J Exp Med 209:597- 606. http://dx.doi.org/10.1084/jem.20111696.
127. Wrammert J, Smith K, Miller J, Langley WA, Kokko K, Larsen C, Zheng NY, Mays I, Garman L, Helms C, James J, Air GM, Capra JD, Ahmed R, Wilson PC. 2008. Rapid cloning of high-Affinity human monoclonal antibodies against influenza virus. Nature 453:667-671. http://dx.doi.org/10.1038/nature06890.
128. Victora GD, Mesin L. 2014. Clonal and cellular dynamics in germinal centers. Curr Opin Immunol 28:90-96. http://dx.doi.org/10.1016/j.coi.2014.02.010.
129. Schaerli P, Willimann K, Lang AB, Lipp M, Loetscher P, Moser B. 2000. CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function. J Exp Med 192:1553-1562. http://dx.doi.org/10.1084/jem.192.11.1553.
130. Kim CH, Rott LS, Clark-Lewis I, Campbell DJ, Wu L, Butcher EC. 2001. Subspecialization of CXCR5-T cells: B helper activity is focused in a germinal center-localized subset of CXCR5- T cells. J Exp Med 193: 1373-1381. http://dx.doi.org/10.1084/jem.193.12.1373.
131. Breitfeld D, Ohl L, Kremmer E, Ellwart J, Sallusto F, Lipp M, Forster R. 2000. Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production. J Exp Med 192:1545-1552. http://dx.doi.org/10.1084/jem.192.11.1545.
132. Jefferis R. 2009. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 8:226-234. http://dx.doi.org/10.1038/nrd2804.
133. Pincetic A, Bournazos S, DiLillo DJ, Maamary J, Wang TT, Dahan R, Fiebiger BM, Ravetch JV. 2014. Type I and type II Fc receptors regulate innate and adaptive immunity. Nat Immunol 15:707-716. http://dx.doi.org/10.1038/ni.2939.
134. Arnold JN, Wormald MR, Sim RB, Rudd PM, Dwek RA. 2007. The impact of glycosylation on the biological function and structure of hu-man immunoglobulins. Annu Rev Immunol 25:21-50. http://dx.doi.org/10.1146/annurev.immunol.25.022106.141702.
135. Selman MH, de Jong SE, Soonawala D, Kroon FP, Adegnika AA, Deelder AM, Hokke CH, Yazdanbakhsh M, Wuhrer M. 2012. Changes in antigen-specific IgG1 Fc N-glycosylation upon influenza and tetanus vaccination. Mol Cell Proteomics 11:M111.014563. http://dx.doi.org/10.1074/mcp.M111.014563.
136. Ackerman ME, Crispin M, Yu X, Baruah K, Boesch AW, Harvey DJ, Dugast AS, Heizen EL, Ercan A, Choi I, Streeck H, Nigrovic PA, Bailey-Kellogg C, Scanlan C, Alter G. 2013. Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. J Clin Invest 123:2183-2192. http://dx.doi.org/10.1172/JCI65708.
137. Vogt MR, Dowd KA, Engle M, Tesh RB, Johnson S, Pierson TC, Diamond MS. 2011. Poorly neutralizing cross-reactive antibodies against the fusion loop of West Nile virus envelope protein protect in vivo via Fcgamma receptor and complement-dependent effector mechanisms. J Virol 85:11567-11580. http://dx.doi.org/10.1128/JVI.05859-11.
138. Chung KM, Nybakken GE, Thompson BS, Engle MJ, Marri A, Fremont DH, Diamond MS. 2006. Antibodies against West Nile virus nonstructural protein NS1 prevent lethal infection through Fc gamma receptor-dependent and -independent mechanisms. J Virol 80:1340- 1351. http://dx.doi.org/10.1128/JVI.80.3.1340-1351.2006.
139. Bournazos S, Klein F, Pietzsch J, Seaman MS, Nussenzweig MC, Ravetch JV. 2014. Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell 158:1243-1253. http://dx.doi.org/10.1016/j.cell.2014.08.023.
140. Hessell AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, Bakker JM, Lanigan CM, Landucci G, Forthal DN, Parren PW, Marx PA, Burton DR. 2007. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449:101-104. http://dx.doi.org/10.1038/nature06106.
141. Balsitis SJ, Williams KL, Lachica R, Flores D, Kyle JL, Mehlhop E, Johnson S, Diamond MS, Beatty PR, Harris E. 2010. Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog 6:e1000790. http://dx.doi.org/10.1371/journal.ppat.1000790.
142. Goncalvez AP, Engle RE, St Claire M, Purcell RH, Lai CJ. 2007. Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc Natl Acad SciUSA 104:9422- 9427. http://dx.doi.org/10.1073/pnas.0703498104.
143. Slifka MK, Antia R, Whitmire JK, Ahmed R. 1998. Humoral immunity due to long-lived plasma cells. Immunity 8:363-372. http://dx.doi.org/10.1016/S1074-7613(00)80541-5.
144. Manz RA, Thiel A, Radbruch A. 1997. Lifetime of plasma cells in the bone marrow. Nature 388:133-134. http://dx.doi.org/10.1038/40540.
145. McHeyzer-Williams LJ, McHeyzer-Williams MG. 2005. Antigenspecific memory B cell development. Annu Rev Immunol 23:487-513. http://dx.doi.org/10.1146/annurev.immunol.23.021704.115732.
146. Dogan I, Bertocci B, Vilmont V, Delbos F, Megret J, Storck S, Reynaud CA, Weill JC. 2009. Multiple layers of B cell memory with different effector functions. Nat Immunol 10:1292-1299. http://dx.doi.org/10.1038/ni.1814.
147. Smith KG, Light A, Nossal GJ, Tarlinton DM. 1997. The extent of affinity maturation differs between the memory and antibody-forming cell compartments in the primary immune response. EMBO J 16:2996- 3006. http://dx.doi.org/10.1093/emboj/16.11.2996.
148. Phan TG, Paus D, Chan TD, Turner ML, Nutt SL, Basten A, Brink R. 2006. High affinity germinal center B cells are actively selected into the plasma cell compartment. J Exp Med 203:2419-2424. http://dx.doi.org/10.1084/jem.20061254.
149. Purtha WE, Tedder TF, Johnson S, Bhattacharya D, Diamond MS. 2011. Memory B cells, but not long-lived plasma cells, possess antigen specificities for viral escape mutants. J Exp Med 208:2599-2606. http://dx.doi.org/10.1084/jem.20110740.
150. Parren PW, Burton DR. 2001. The antiviral activity of antibodies in vitro and in vivo. Adv Immunol 77:195-262. http://dx.doi.org/10.1016/S0065-2776(01)77018-6.
151. Klasse PJ, Sattentau QJ. 2002. Occupancy and mechanism in antibodymediated neutralization of animal viruses. J Gen Virol 83:2091-2108. http://dx.doi.org/10.1099/0022-1317-83-9-2091.
152. Lanzavecchia A, Corti D, Sallusto F. 2007. Human monoclonal antibodies by immortalization of memory B cells. Curr Opin Biotechnol 18:523-528. http://dx.doi.org/10.1016/j.copbio.2007.10.011.
153. Della-Porta AJ, Westaway EG. 1978. A multi-hit model for the neutralization of animal viruses. J Gen Virol 38:1-19. http://dx.doi.org/10.1099/0022-1317-38-1-1.
154. Dulbecco R, Vogt M, Strickland AG. 1956. A study of the basic aspects of neutralization of two animal viruses, Western equine encephalitis virus and poliomyelitis virus. Virology 2:162-205. http://dx.doi.org/10.1016/0042-6822(56)90017-4.
155. Taylor HP, Armstrong SJ, Dimmock NJ. 1987. Quantitative relationships between an influenza virus and neutralizing antibody. Virology 159:288-298. http://dx.doi.org/10.1016/0042-6822(87)90466-1.
156. Rappaport I. 1970. An analysis of the inactivation of MS2 bacteriophage with antiserum. J Gen Virol 6:25-32. http://dx.doi.org/10.1099/0022-1317-6-1-25.
157. Icenogle J, Shiwen H, Duke G, Gilbert S, Rueckert R, Anderegg J. 1983. Neutralization of poliovirus by a monoclonal antibody: kinetics and stoichiometry. Virology 127:412- 425. http://dx.doi.org/10.1016/0042-6822(83)90154-X.
158. Colonno RJ, Callahan PL, Leippe DM, Rueckert RR, Tomassini JE. 1989. Inhibition of rhinovirus attachment by neutralizing monoclonal antibodies and their Fab fragments. J Virol 63:36-42.
159. Smith TJ, Olson NH, Cheng RH, Liu H, Chase ES, Lee WM, Leippe DM, Mosser AG, Rueckert RR, Baker TS. 1993. Structure of human rhinovirus complexed with Fab fragments from a neutralizing antibody. J Virol 67:1148-1158.
160. Pierson TC, Xu Q, Nelson S, Oliphant T, Nybakken GE, Fremont DH, Diamond MS. 2007. The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe 1:135-145. http://dx.doi.org/10.1016/j.chom.2007.03.002.
161. Roden RB, Weissinger EM, Henderson DW, Booy F, Kirnbauer R, Mushinski JF, Lowy DR, Schiller JT. 1994. Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins. J Virol 68: 7570-7574.
162. Flamand A, Raux H, Gaudin Y, Ruigrok RW. 1993. Mechanisms of rabies virus neutralization. Virology 194:302-313. http://dx.doi.org/10.1006/viro.1993.1261.
163. Raux H, Coulon P, Lafay F, Flamand A. 1995. Monoclonal antibodies which recognize the acidic configuration of the rabies glycoprotein at the surface of the virion can be neutralizing. Virology 210:400-408. http://dx.doi.org/10.1006/viro.1995.1356.
164. Mehlhop E, Nelson S, Jost CA, Gorlatov S, Johnson S, Fremont DH, Diamond MS, Pierson TC. 2009. Complement protein C1q reduces the stoichiometric threshold for antibody-mediated neutralization of West Nile virus. Cell Host Microbe 6:381-391. http://dx.doi.org/10.1016/j.chom.2009.09.003.
165. Pierson TC, Diamond MS. 2015. A game of numbers: The stoichiometry of antibody-mediated neutralization of flavivirus infection. Prog Mol Biol Transl Sci 129:141-166. http://dx.doi.org/10.1016/bs.pmbts.2014.10.005.
166. Dowd KA, Jost CA, Durbin AP, Whitehead SS, Pierson TC. 2011. A dynamic landscape for antibody binding modulates antibody-mediated neutralization of West Nile virus. PLoS Pathog 7:e1002111. http://dx.doi.org/10.1371/journal.ppat.1002111.
167. Nybakken GE, Oliphant T, Johnson S, Burke S, Diamond MS, Fremont DH. 2005. Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature 437:764-769. http://dx.doi.org/10.1038/nature03956.
168. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, Wrin T, Simek MD, Fling S, Mitcham JL, Lehrman JK, Priddy FH, Olsen OA, Frey SM, Hammond PW, Protocol G Principal Investigators, Kaminsky S, Zamb T, Moyle M, Koff WC, Poignard P, Burton DR. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:285-289. http://dx.doi.org/10.1126/science.1178746.
169. Rouvinski A, Guardado-Calvo P, Barba-Spaeth G, Duquerroy S, Vaney MC, Kikuti CM, Navarro Sanchez ME, Dejnirattisai W, Wongwiwat W, Haouz A, Girard-Blanc C, Petres S, Shepard WE, Despres P, Arenzana-Seisdedos F, Dussart P, Mongkolsapaya J, Screaton GR, Rey FA. 2015. Recognition determinants of broadly neutralizing human antibodies against dengue viruses. Nature 520:109-113. http://dx.doi.org/10.1038/nature14130.
170. Kaufmann B, Vogt MR, Goudsmit J, Holdaway HA, Aksyuk AA, Chipman PR, Kuhn RJ, Diamond MS, Rossmann MG. 2010. Neutralization of West Nile virus by cross-linking of its surface proteinswith Fab fragments of the human monoclonal antibody CR4354. Proc Natl Acad Sci U S A 107:18950 -18955. http://dx.doi.org/10.1073/pnas.1011036107.
171. Fibriansah G, Tan JL, Smith SA, de Alwis R, Ng TS, Kostyuchenko VA, Jadi RS, Kukkaro P, de Silva AM, Crowe JE, Lok SM. 2015. A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins. Nat Commun 6:6341. http://dx.doi.org/10.1038/ncomms7341.
172. Fibriansah G, Ibarra KD, Ng TS, Smith SA, Tan JL, Lim XN, Ooi JS, Kostyuchenko VA, Wang J, de Silva AM, Harris E, Crowe JE Jr, Lok SM. 2015. Dengue virus cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers. Science 349:88-91. http://dx.doi.org/10.1126/science.aaa8651.
173. Pierson TC, Fremont DH, Kuhn RJ, Diamond MS. 2008. Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development. Cell Host Microbe 4:229-238. http://dx.doi.org/10.1016/j.chom.2008.08.004.
174. Lee PD, Mukherjee S, Edeling MA, Dowd KA, Austin SK, Manhart CJ, Diamond MS, Fremont DH, Pierson TC. 2013. The Fc region of an antibody impacts the neutralization of West Nile viruses in different maturation states. J Virol 87:13729-13740. http://dx.doi.org/10.1128/JVI.02340-13.
175. Lok SM, Kostyuchenko V, Nybakken GE, Holdaway HA, Battisti AJ, Sukupolvi-Petty S, Sedlak D, Fremont DH, Chipman PR, Roehrig JT, Diamond MS, Kuhn RJ, Rossmann MG. 2008. Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat Struct Mol Biol 15:312-317. http://dx.doi.org/10.1038/nsmb.1382.
176. He RT, Innis BL, Nisalak A, Usawattanakul W, Wang S, Kalayanarooj S, Anderson R. 1995. Antibodies that block virus attachment to Vero cells are a major component of the human neutralizing antibody response against dengue virus type 2. J Med Virol 45:451-461. http://dx.doi.org/10.1002/jmv.1890450417.
177. Thompson BS, Moesker B, Smit JM, Wilschut J, Diamond MS, Fremont DH. 2009. A therapeutic antibody against West Nile virus neutralizes infection by blocking fusion within endosomes. PLoS Pathog 5:e1000453. http://dx.doi.org/10.1371/journal.ppat.1000453.
178. Lai CJ, Goncalvez AP, Men R, Wernly C, Donau O, Engle RE, Purcell RH. 2007. Epitope determinants of a chimpanzee dengue virus type 4 (DENV-4)-neutralizing antibody and protection against DENV-4 challenge in mice and rhesus monkeys by passively transferred humanized antibody. J Virol 81:12766 -12774. http://dx.doi.org/10.1128/JVI.01420-07.
179. Gollins SW, Porterfield JS. 1986. A new mechanism for the neutralization of enveloped viruses by antiviral antibody. Nature 321:244-246. http://dx.doi.org/10.1038/321244a0.
180. Kaufmann B, Nybakken GE, Chipman PR, Zhang W, Diamond MS, Fremont DH, Kuhn RJ, Rossmann MG. 2006. West Nile virus in complex with the Fab fragment of a neutralizing monoclonal antibody. Proc Natl Acad Sci U S A 103:12400-12404. http://dx.doi.org/10.1073/pnas.0603488103.
181. Mandel B. 1961. Reversibility of the reaction between polio-virus and neutralizing antibody of rabbit origin. Virology 14:316-328. http://dx.doi.org/10.1016/0042-6822(61)90317-8.
182. Ruprecht CR, Krarup A, Reynell L, Mann AM, Brandenberg OF, Berlinger L, Abela IA, Regoes RR, Gunthard HF, Rusert P, Trkola A. 2011. MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1. J Exp Med 208:439-454. http://dx.doi.org/10.1084/jem.20101907.
183. Davies DR, Cohen GH. 1996. Interactions of protein antigens with antibodies. Proc Natl Acad Sci U S A 93:7-12. http://dx.doi.org/10.1073/pnas.93.1.7.
184. Kiermayr S, Stiasny K, Heinz FX. 2009. Impact of quaternary organization on the antigenic structure of the tick-borne encephalitis virus envelope glycoprotein E. J Virol 83:8482-8491. http://dx.doi.org/10.1128/JVI.00660-09.
185. Heinz FX, Mandl C, Berger R, Tuma W, Kunz C. 1984. Antibody-induced conformational changes result in enhanced avidity of antibodies to different antigenic sites on the tick-borne encephalitis virus glycoprotein. Virology 133:25-34. http://dx.doi.org/10.1016/0042-6822(84)90422-7.
186. Renzette N, Bhattacharjee B, Jensen JD, Gibson L, Kowalik TF. 2011. Extensive genome-wide variability of human cytomegalovirus in congenitally infected infants. PLoS Pathog 7:e1001344. http://dx.doi.org/10.1371/journal.ppat.1001344.
187. Sanjuan R, Nebot MR, Chirico N, Mansky LM, Belshaw R. 2010. Viral mutation rates. J Virol 84:9733-9748. http://dx.doi.org/10.1128/JVI.00694-10.
188. Heaton NS, Sachs D, Chen CJ, Hai R, Palese P. 2013. Genome-wide mutagenesis of influenza virus reveals unique plasticity of the hemagglutinin and NS1 proteins. Proc Natl Acad Sci U S A 110:20248-20253. http://dx.doi.org/10.1073/pnas.1320524110.
189. Lindesmith LC, Donaldson EF, Baric RS. 2011. Norovirus GII.4 strain antigenic variation. J Virol 85:231-242. http://dx.doi.org/10.1128/JVI.01364-10.
190. Das SR, Hensley SE, Ince WL, Brooke CB, Subba A, Delboy MG, Russ G, Gibbs JS, Bennink JR, Yewdell JW. 2013. Defining influenza A virus hemagglutinin antigenic drift by sequential monoclonal antibody selection. Cell Host Microbe 13:314-323. http://dx.doi.org/10.1016/j.chom.2013.02.008.
191. Overbaugh J, Bangham CR. 2001. Selection forces and constraints on retroviral sequence variation. Science 292:1106-1109. http://dx.doi.org/10.1126/science.1059128.
192. Yewdell JW. 2011. Viva la revolucion: Rethinking influenza A virus antigenic drift. Curr Opin Virol 1:177-183. http://dx.doi.org/10.1016/j.coviro.2011.05.005.
193. Smith DJ, Lapedes AS, de Jong JC, Bestebroer TM, Rimmelzwaan GF, Osterhaus AD, Fouchier RA. 2004. Mapping the antigenic and genetic evolution of influenza virus. Science 305:371-376. http://dx.doi.org/10.1126/science.1097211.
194. Frost SD, Wrin T, Smith DM, Kosakovsky Pond SL, Liu Y, Paxinos E, Chappey C, Galovich J, Beauchaine J, Petropoulos CJ, Little SJ, Richman DD. 2005. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci U S A 102:18514-18519. http://dx.doi.org/10.1073/pnas.0504658102.
195. Monath TP. 2005. Yellow fever vaccine. Expert Rev Vaccines 4:553-574. http://dx.doi.org/10.1586/14760584.4.4.553.
196. Coffey LL, Forrester N, Tsetsarkin K, Vasilakis N, Weaver SC. 2013. Factors shaping the adaptive landscape for arboviruses: implications for the emergence of disease. Future Microbiol 8:155-176. http://dx.doi.org/10.2217/fmb.12.139.
197. Fulton BO, Sachs D, Beaty SM, Won ST, Lee B, Palese P, Heaton NS. 2015. Mutational analysis of measles virus suggests constraints on antigenic variation of the glycoproteins. Cell Rep 11:1331-1338. http://dx.doi.org/10.1016/j.celrep.2015.04.054.
198. Thyagarajan B, Bloom JD. 2014. The inherent mutational tolerance and antigenic evolvability of influenza hemagglutinin. eLife 3:e03300. http://dx.doi.org/10.7554/eLife.03300.
199. Rossmann MG. 1989. The canyon hypothesis. Hiding the host cell receptor attachment site on a viral surface from immune surveillance. J Biol Chem 264:14587-14590.
200. Smith TJ, Chase ES, Schmidt TJ, Olson NH, Baker TS. 1996. Neutralizing antibody to human rhinovirus 14 penetrates the receptor-binding canyon. Nature 383:350-354. http://dx.doi.org/10.1038/383350a0.
201. Kwong PD, Doyle ML, Casper DJ, Cicala C, Leavitt SA, Majeed S, Steenbeke TD, Venturi M, Chaiken I, Fung M, Katinger H, Parren PW, Robinson J, Van Ryk D, Wang L, Burton DR, Freire E, Wyatt R, Sodroski J, Hendrickson WA, Arthos J. 2002. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420:678 - 682. http://dx.doi.org/10.1038/nature01188.
202. Lin HE, Tsai WY, Liu IJ, Li PC, Liao MY, Tsai JJ, Wu YC, Lai CY, Lu CH, Huang JH, Chang GJ, Wu HC, Wang WK. 2012. Analysis of epitopes on dengue virus envelope protein recognized by monoclonal antibodies and polyclonal human sera by a high throughput assay. PLoS Negl Trop Dis 6:e1447. http://dx.doi.org/10.1371/journal.pntd.0001447.
203. Lai CY, Tsai WY, Lin SR, Kao CL, Hu HP, King CC, Wu HC, Chang GJ, Wang WK. 2008. Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly crossreactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. J Virol 82:6631-6643. http://dx.doi.org/10.1128/JVI.00316-08.
204. Throsby M, Geuijen C, Goudsmit J, Bakker AQ, Korimbocus J, Kramer RA, Clijsters-van der Horst M, de Jong M, Jongeneelen M, Thijsse S, Smit R, Visser TJ, Bijl N, Marissen WE, Loeb M, Kelvin DJ, Preiser W, ter Meulen J, de Kruif J. 2006. Isolation and characterization of human monoclonal antibodies from individuals in-fected with West Nile virus. J Virol 80:6982- 6992. http://dx.doi.org/10.1128/JVI.00551-06.
205. Cherrier MV, Kaufmann B, Nybakken GE, Lok SM, Warren JT, Chen BR, Nelson CA, Kostyuchenko VA, Holdaway HA, Chipman PR, Kuhn RJ, Diamond MS, Rossmann MG, Fremont DH. 2009. Structural basis for the preferential recognition of immature flaviviruses by a fusion- loop antibody. EMBO J 28:3269-3276. http://dx.doi.org/10.1038/emboj.2009.245.
206. Oliphant T, Nybakken GE, Engle M, Xu Q, Nelson CA, Sukupolvi- Petty S, Marri A, Lachmi BE, Olshevsky U, Fremont DH, Pierson TC, Diamond MS. 2006. Antibody recognition and neutralization determinants on domains I and II of West Nile virus envelope protein. J Virol 80:12149-12159. http://dx.doi.org/10.1128/JVI.01732-06.
207. Austin SK, Dowd KA, Shrestha B, Nelson CA, Edeling MA, Johnson S, Pierson TC, Diamond MS, Fremont DH. 2012. Structural basis of differential neutralization of DENV-1 genotypes by an antibody that recognizes a cryptic epitope. PLoS Pathog 8:e1002930. http://dx.doi.org/10.1371/journal.ppat.1002930.
208. Li Q, Yafal AG, Lee YM, Hogle J, Chow M. 1994. Poliovirus neutralization by antibodies to internal epitopes of VP4 and VP1 results from reversible exposure of these sequences at physiological temperature. J Virol 68:3965-3970.
209. Sabo MC, Luca VC, Ray SC, Bukh J, Fremont DH, Diamond MS. 2012. Hepatitis C virus epitope exposure and neutralization by antibodies is affected by time and temperature. Virology 422:174-184. http://dx.doi.org/10.1016/j.virol.2011.10.023.
210. Lindesmith LC, Donaldson EF, Beltramello M, Pintus S, Corti D, Swanstrom J, Debbink K, Jones TA, Lanzavecchia A, Baric RS. 2014. Particle conformation regulates antibody access to a conserved GII.4 norovirus blockade epitope. J Virol 88:8826-8842. http://dx.doi.org/10.1128/JVI.01192-14.
211. Davenport TM, Guttman M, Guo W, Cleveland B, Kahn M, Hu SL, Lee KK. 2013. Isolate-specific differences in the conformational dynamics and antigenicity of HIV-1 gp120. J Virol 87:10855-10873. http://dx.doi.org/10.1128/JVI.01535-13.
212. Sukupolvi-Petty S, Brien JD, Austin SK, Shrestha B, Swayne S, Kahle K, Doranz BJ, Johnson S, Pierson TC, Fremont DH, Diamond MS. 2013. Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection. J Virol 87:8826-8842. http://dx.doi.org/10.1128/JVI.01314-13.
213. Li L, Coelingh KL, Britt WJ. 1995. Human cytomegalovirus neutralizing antibody-resistant phenotype is associated with reduced expression of glycoprotein H. J Virol 69:6047-6053.
214. Klein JS, Bjorkman PJ. 2010. Few and far between: how HIV may be evading antibody avidity. PLoS Pathog 6:e1000908. http://dx.doi.org/10.1371/journal.ppat.1000908.
215. Galimidi RP, Klein JS, Politzer MS, Bai S, Seaman MS, Nussenzweig MC, West AP Jr, Bjorkman PJ. 2015. Intra-spike crosslinking overcomes antibody evasion by HIV-1. Cell 160:433-446. http://dx.doi.org/10.1016/j.cell.2015.01.016.
216. Edeling MA, Austin SK, Shrestha B, Dowd KA, Mukherjee S, Nelson CA, Johnson S, Mabila MN, Christian EA, Rucker J, Pierson TC, Diamond MS, Fremont DH. 2014. Potent dengue virus neutralization by a therapeutic antibody with low monovalent affinity requires bivalent engagement. PLoS Pathog 10:e1004072. http://dx.doi.org/10.1371/journal.ppat.1004072.
217. Vigerust DJ, Shepherd VL. 2007. Virus glycosylation: Role in virulence and immune interactions. Trends Microbiol 15:211-218. http://dx.doi.org/10.1016/j.tim.2007.03.003.
218. Helle F, Goffard A, Morel V, Duverlie G, McKeating J, Keck ZY, Foung S, Penin F, Dubuisson J, Voisset C. 2007. The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein. J Virol 81:8101-8111. http://dx.doi.org/10.1128/JVI.00127-07.
219. Sagar M, Wu X, Lee S, Overbaugh J. 2006. Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. J Virol 80:9586-9598. http://dx.doi.org/10.1128/JVI.00141-06.
220. Chackerian B, Rudensey LM, Overbaugh J. 1997. Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies. J Virol 71:7719-7727.
221. Smith SA, de Alwis AR, Kose N, Harris E, Ibarra KD, Kahle KM, Pfaff JM, Xiang X, Doranz BJ, de Silva AM, Austin SK, Sukupolvi-Petty S, Diamond MS, Crowe JE Jr. 2013. The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein. mBio 4:e00873-13. http://dx.doi.org/10.1128/mBio.00873-13.
222. Williams KL, Sukupolvi-Petty S, Beltramello M, Johnson S, Sallusto F, Lanzavecchia A, Diamond MS, Harris E. 2013. Therapeutic efficacy of antibodies lacking Fcgamma receptor binding against lethal dengue virus infection is due to neutralizing potency and blocking of enhancing antibodies. PLoS Pathog 9:e1003157. http://dx.doi.org/10.1371/journal.ppat.1003157.
223. Dejnirattisai W, Wongwiwat W, Supasa S, Zhang X, Dai X, Rouvinski A, Jumnainsong A, Edwards C, Quyen NT, Duangchinda T, Grimes JM, Tsai WY, Lai CY, Wang WK, Malasit P, Farrar J, Simmons CP, Zhou ZH, Rey FA, Mongkolsapaya J, Screaton GR. 2015. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat Immunol 16:170-177. http://dx.doi.org/10.1038/ni.3058.
224. Lin TY, Dowd KA, Manhart CJ, Nelson S, Whitehead SS, Pierson TC. 2012. A novel approach for the rapid mutagenesis and directed evolution of the structural genes of West Nile virus. J Virol 86:3501-3512. http://dx.doi.org/10.1128/JVI.06435-11.
225. Crill WD, Hughes HR, Delorey MJ, Chang GJ. 2009. Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus- like particle antigens. PLoS One 4:e4991. http://dx.doi.org/10.1371/journal.pone.0004991.
226. Williams KL, Wahala WM, Orozco S, de Silva AM, Harris E. 2012. Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo. Virology 429:12-20. http://dx.doi.org/10.1016/j.virol.2012.03.003.
227. Wahala WM, Kraus AA, Haymore LB, Accavitti-Loper MA, de Silva AM. 2009. Dengue virus neutralization by human immune sera: Role of envelope protein domain III-reactive antibody. Virology 392:103-113. http://dx.doi.org/10.1016/j.virol.2009.06.037.
228. VanBlargan LA, Mukherjee S, Dowd KA, Durbin AP, Whitehead SS, Pierson TC. 2013. The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein. PLoS Pathog 9:e1003761. http://dx.doi.org/10.1371/journal.ppat.1003761.
229. Scheid JF, Mouquet H, Feldhahn N, Walker BD, Pereyra F, Cutrell E, Seaman MS, Mascola JR, Wyatt RT, Wardemann H, Nussenzweig MC. 2009. A method for identification of HIV gp140 binding memory B cells in human blood. J Immunol Methods 343:65-67. http://dx.doi.org/10.1016/j.jim.2008.11.012.
230. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, Zhou T, Schmidt SD, Wu L, Xu L, Longo NS, McKee K, O'Dell S, Louder MK, Wycuff DL, Feng Y, Nason M, Doria-Rose N, Connors M, Kwong PD, Roederer M, Wyatt RT, Nabel GJ, Mascola JR. 2010. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329:856-861. http://dx.doi.org/10.1126/science.1187659.
231. Scheid JF, Mouquet H, Ueberheide B, Diskin R, Klein F, Oliveira TY, Pietzsch J, Fenyo D, Abadir A, Velinzon K, Hurley A, Myung S, Boulad F, Poignard P, Burton DR, Pereyra F, Ho DD, Walker BD, Seaman MS, Bjorkman PJ, Chait BT, Nussenzweig MC. 2011. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333:1633-1637. http://dx.doi.org/10.1126/science.1207227.
232. Hicar MD, Chen X, Briney B, Hammonds J, Wang JJ, Kalams S, Spearman PW, Crowe JE Jr. 2010. Pseudovirion particles bearing native HIV envelope trimers facilitate a novel method for generating human neutralizing monoclonal antibodies against HIV. J Acquir Immune Defic Syndr 54: 223-235. http://dx.doi.org/10.1097/QAI.0b013e3181dc98a3.
233. Scherer EM, Smith RA, Simonich CA, Niyonzima N, Carter JJ, Galloway DA. 2014. Characteristics of memory B cells elicited by a highly efficaciousHPVvaccine in subjects with no pre-existing immunity. PLoS Pathog 10:e1004461. http://dx.doi.org/10.1371/journal.ppat.1004461.
234. Smith SA, de Alwis AR, Kose N, Jadi RS, de Silva AM, Crowe JE Jr. 2014. Isolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals thepresence of diverse novel functional groups of antibody clones. J Virol 88:12233-12241. http://dx.doi.org/10.1128/JVI.00247-14.
235. Smith SA, de Alwis R, Kose N, Durbin AP, Whitehead SS, de Silva AM, Crowe JE Jr. 2013. Human monoclonal antibodies derived from memory B cells following live attenuated dengue virus vaccination or natural infection exhibit similar characteristics. J Infect Dis 207:1898-1908. http://dx.doi.org/10.1093/infdis/jit119.
236. Oliphant T, Nybakken GE, Austin SK, Xu Q, Bramson J, Loeb M, Throsby M, Fremont DH, Pierson TC, Diamond MS. 2007. Induction of epitope-specific neutralizing antibodies against West Nile virus. J Virol 81:11828-11839. http://dx.doi.org/10.1128/JVI.00643-07.
237. Simonich CA, Williams KL, Verkerke HP, Williams JA, Nduati R, Lee KK, Overbaugh J. 2016. HIV-1 neutralizing antibodies with limited hypermutation from an infant. Cell 166:77-87. http://dx.doi.org/10.1016/j.cell.2016.05.055.
238. MacLeod DT, Choi NM, Briney B, Garces F, Ver LS, Landais E, Murrell B, Wrin T, Kilembe W, Liang CH, Ramos A, Bian CB, Wickramasinghe L, Kong L, Eren K, Wu CY, Wong CH, IAVI Protocol C Investigators and the IAVI African HIV Research Network, Kosakovsky Pond SL, Wilson IA, Burton DR, Poignard P. 2016. Early antibody lineage diversification and independent limb maturation lead to broad HIV-1 neutralization targeting the Env high-mannose patch. Immunity 44:1215-1226. http://dx.doi.org/10.1016/j.immuni.2016.04.016.
239. Wu X, Zhou T, Zhu J, Zhang B, Georgiev I, Wang C, Chen X, Longo NS, Louder M, McKee K, O'Dell S, Perfetto S, Schmidt SD, Shi W, Wu L, Yang Y, Yang ZY, Yang Z, Zhang Z, Bonsignori M, Crump JA, Kapiga SH, Sam NE, Haynes BF, Simek M, Burton DR, Koff WC, Doria-Rose NA, Connors M, NISC Comparative Sequencing Program, Mullikin JC, Nabel GJ, Roederer M, Shapiro L, Kwong PD, Mascola JR. 2011. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333:1593-1602. http://dx.doi.org/10.1126/science.1207532.
240. Briney BS, Willis JR, Crowe JE Jr. 2012. Human peripheral blood antibodies with long HCDR3s are established primarily at original recombination using a limited subset of germline genes. PLoS One 7:e36750. http://dx.doi.org/10.1371/journal.pone.0036750.
241. Scharf L, West AP Jr, Gao H, Lee T, Scheid JF, Nussenzweig MC, Bjorkman PJ, Diskin R. 2013. Structural basis for HIV-1 gp120 recognition by a germ-line version of a broadly neutralizing antibody. Proc Natl Acad Sci U S A 110:6049-6054. http://dx.doi.org/10.1073/pnas.1303682110.
242. Zhou T, Zhu J, Wu X, Moquin S, Zhang B, Acharya P, Georgiev IS, Altae-Tran HR, Chuang GY, Joyce MG, Kwon YD, Longo NS, Louder MK, Luongo T, McKee K, Schramm CA, Skinner J, Yang Y, Yang Z, Zhang Z, Zheng A, Bonsignori M, Haynes BF, Scheid JF, Nussenzweig MC, Simek M, Burton DR, Koff WC, NISC Comparative Sequencing Program, Mullikin JC, Connors M, Shapiro L, Nabel GJ, Mascola JR, Kwong PD. 2013. Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. Immunity 39:245-258. http://dx.doi.org/10.1016/j.immuni.2013.04.012.
243. Parameswaran P, Liu Y, Roskin KM, Jackson KK, Dixit VP, Lee JY, Artiles KL, Zompi S, Vargas MJ, Simen BB, Hanczaruk B, McGowan KR, Tariq MA, Pourmand N, Koller D, Balmaseda A, Boyd SD, Harris E, Fire AZ. 2013. Convergent antibody signatures in human dengue. Cell Host Microbe 13:691-700. http://dx.doi.org/10.1016/j.chom.2013.05.008.
244. Jackson KJ, Liu Y, Roskin KM, Glanville J, Hoh RA, Seo K, Marshall EL, Gurley TC, Moody MA, Haynes BF, Walter EB, Liao HX, Albrecht RA, Garcia-Sastre A, Chaparro-Riggers J, Rajpal A, Pons J, Simen BB, Hanczaruk B, Dekker CL, Laserson J, Koller D, Davis MM, Fire AZ, Boyd SD. 2014. Human responses to influenza vaccination show seroconversion signatures and convergent antibody rearrangements. Cell Host Microbe 16: 105-114. http://dx.doi.org/10.1016/j.chom.2014.05.013.
245. Vratskikh O, Stiasny K, Zlatkovic J, Tsouchnikas G, Jarmer J, Karrer U, Roggendorf M, Roggendorf H, Allwinn R, Heinz FX. 2013. Dissection of antibody specificities induced by yellow fever vaccination. PLoS Pathog 9:e1003458. http://dx.doi.org/10.1371/journal.ppat.1003458.
246. Jarmer J, Zlatkovic J, Tsouchnikas G, Vratskikh O, Strauss J, Aberle JH, Chmelik V, Kundi M, Stiasny K, Heinz FX. 2014. Variation of the specificity of the human antibody responses after tick-borne encephalitis virus infection and vaccination. J Virol 88:13845-13857. http://dx.doi.org/10.1128/JVI.02086-14.
247. Gromowski GD, Barrett ND, Barrett AD. 2008. Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus. J Virol 82:8828-8837. http://dx.doi.org/10.1128/JVI.00606-08.
248. Oliphant T, Engle M, Nybakken GE, Doane C, Johnson S, Huang L, Gorlatov S, Mehlhop E, Marri A, Chung KM, Ebel GD, Kramer LD, Fremont DH, Diamond MS. 2005. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med 11:522-530. http://dx.doi.org/10.1038/nm1240.
249. Wahala WM, Huang C, Butrapet S, White LJ, de Silva AM. 2012. Recombinant dengue type 2 viruses with altered E protein domain III epitopes are efficiently neutralized by human immune sera. J Virol 86: 4019-4023. http://dx.doi.org/10.1128/JVI.06871-11.
250. Gallichotte EN, Widman DG, Yount BL, Wahala WM, Durbin A, Whitehead S, Sariol CA, Crowe JE Jr, de Silva AM, Baric RS. 2015. A new quaternary structure epitope on dengue virus serotype 2 is the target of durable type-specific neutralizing antibodies. mBio 6:e01461-15. http://dx.doi.org/10.1128/mBio.01461-15.
251. Durbin AP, McArthur J, Marron JA, Blaney JE Jr, Thumar B, Wanionek K, Murphy BR, Whitehead SS. 2006. The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers. Hum Vaccin 2:167-173. http://dx.doi.org/10.4161/hv.2.4.2944.
252. Durbin AP, Whitehead SS, Shaffer D, Elwood D, Wanionek K, Thumar B, Blaney JE, Murphy BR, Schmidt AC. 2011. A single dose of the DENV-1 candidate vaccine rDEN1Delta30 is strongly immunogenic and induces resistance to a second dose in a randomized trial. PLoS Negl Trop Dis 5:e1267. http://dx.doi.org/10.1371/journal.pntd.0001267.
253. Durbin AP, Kirkpatrick BD, Pierce KK, Elwood D, Larsson CJ, Lindow JC, Tibery C, Sabundayo BP, Shaffer D, Talaat KR, Hynes NA, Wanionek K, Carmolli MP, Luke CJ, Murphy BR, Subbarao K, Whitehead SS. 2013. A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: A randomized, double-blind clinical trial. J Infect Dis 207:957- 965. http://dx.doi.org/10.1093/infdis/jis936.
254. Durbin AP, Kirkpatrick BD, Pierce KK, Schmidt AC, Whitehead SS. 2011. Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine. Vaccine 29:7242-7250. http://dx.doi.org/10.1016/j.vaccine.2011.07.023.
255. Dhillon AK, Donners H, Pantophlet R, Johnson WE, Decker JM, Shaw GM, Lee FH, Richman DD, Doms RW, Vanham G, Burton DR. 2007. Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol 81:6548-6562. http://dx.doi.org/10.1128/JVI.02749-06.
256. Walker LM, Simek MD, Priddy F, Gach JS, Wagner D, Zwick MB, Phogat SK, Poignard P, Burton DR. 2010. A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog 6:e1001028. http://dx.doi.org/10.1371/journal.ppat.1001028.
257. Tomaras GD, Binley JM, Gray ES, Crooks ET, Osawa K, Moore PL, Tumba N, Tong T, Shen X, Yates NL, Decker J, Wibmer CK, Gao F, Alam SM, Easterbrook P, Abdool Karim S, Kamanga G, Crump JA, Cohen M, Shaw GM, Mascola JR, Haynes BF, Montefiori DC, Morris L. 2011. Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. J Virol 85:11502-11519. http://dx.doi.org/10.1128/JVI.05363-11.
258. Li Y, Svehla K, Louder MK, Wycuff D, Phogat S, Tang M, Migueles SA, Wu X, Phogat A, Shaw GM, Connors M, Hoxie J, Mascola JR, Wyatt R. 2009. Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J Virol 83:1045-1059. http://dx.doi.org/10.1128/JVI.01992-08.
259. Scheid JF, Mouquet H, Feldhahn N, Seaman MS, Velinzon K, Pietzsch J, Ott RG, Anthony RM, Zebroski H, Hurley A, Phogat A, Chakrabarti B, Li Y, Connors M, Pereyra F, Walker BD, Wardemann H, Ho D, Wyatt RT, Mascola JR, Ravetch JV, Nussenzweig MC. 2009. Broad diversity of neutralizing antibodies isolated from memory B cells in HIVinfected individuals. Nature 458:636-640. http://dx.doi.org/10.1038/nature07930.
260. Mouquet H, Klein F, Scheid JF, Warncke M, Pietzsch J, Oliveira TY, Velinzon K, Seaman MS, Nussenzweig MC. 2011. Memory B cell anti-bodies to HIV-1 gp140 cloned from individuals infected with clade A and B viruses. PLoS One 6:e24078. http://dx.doi.org/10.1371/journal.pone.0024078.
261. Goo L, Chohan V, Nduati R, Overbaugh J. 2014. Early development of broadly neutralizing antibodies in HIV-1-infected infants. Nat Med 20: 655-658. http://dx.doi.org/10.1038/nm.3565.
262. Cortez V, Wang B, Dingens A, Chen MM, Ronen K, Georgiev IS, McClelland RS, Overbaugh J. 2015. The broad neutralizing antibody responses after HIV-1 superinfection are not dominated by antibodies directed to epitopes common in single infection. PLoS Pathog 11: E1004973. http://dx.doi.org/10.1371/journal.ppat.1004973.
263. Moore PL, Gray ES, Wibmer CK, Bhiman JN, Nonyane M, Sheward DJ, Hermanus T, Bajimaya S, Tumba NL, Abrahams MR, Lambson BE, Ranchobe N, Ping L, Ngandu N, Abdool Karim Q, Abdool Karim SS, Swanstrom RI, Seaman MS, Williamson C, Morris L. 2012. Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat Med 18:1688-1692. http://dx.doi.org/10.1038/nm.2985.
264. Liao HX, Lynch R, Zhou T, Gao F, Alam SM, Boyd SD, Fire AZ, Roskin KM, Schramm CA, Zhang Z, Zhu J, Shapiro L, NISC Comparative Sequencing Program, Mullikin JC, Gnanakaran S, Hraber P, Wiehe K, Kelsoe G, Yang G, Xia SM, Montefiori DC, Parks R, Lloyd KE, Scearce RM, Soderberg KA, Cohen M, Kamanga G, Louder MK, Tran LM, Chen Y, Cai F, Chen S, Moquin S, Du X, Joyce MG, Srivatsan S, Zhang B, Zheng A, Shaw GM, Hahn BH, Kepler TB, Korber BT, Kwong PD, Mascola JR, Haynes BF. 2013. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 496: 469-476. http://dx.doi.org/10.1038/nature12053.
265. Wibmer CK, Bhiman JN, Gray ES, Tumba N, Abdool Karim SS, Williamson C, Morris L, Moore PL. 2013. Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes. PLoS Pathog 9:e1003738. http://dx.doi.org/10.1371/journal.ppat.1003738.
266. Murphy MK, Yue L, Pan R, Boliar S, Sethi A, Tian J, Pfafferot K, Karita E, Allen SA, Cormier E, Goepfert PA, Borrow P, Robinson JE, Gnanakaran S, Hunter E, Kong XP, Derdeyn CA. 2013. Viral escape from neutralizing antibodies in early subtypeAHIV-1 infection drives an increase in autologous neutralization breadth. PLoS Pathog 9:e1003173. http://dx.doi.org/10.1371/journal.ppat.1003173.
267. Gao F, Bonsignori M, Liao HX, Kumar A, Xia SM, Lu X, Cai F, Hwang KK, Song H, Zhou T, Lynch RM, Alam SM, Moody MA, Ferrari G, Berrong M, Kelsoe G, Shaw GM, Hahn BH, Montefiori DC, Kamanga G, Cohen MS, Hraber P, Kwong PD, Korber BT, Mascola JR, Kepler TB, Haynes BF. 2014. Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies. Cell 158:481-491. http://dx.doi.org/10.1016/j.cell.2014.06.022.
268. Kwong PD, Mascola JR, Nabel GJ. 2011. Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1. Cold Spring Harb Perspect Med 1:a007278. http://dx.doi.org/10.1101/cshperspect.a007278.
269. Widman DG, Baric RS. 2015. Dengue virus envelope protein domain I/II hinge: A key target for dengue virus vaccine design? Expert Rev Vaccines 14:5-8. http://dx.doi.org/10.1586/14760584.2015.961431.
270. Krammer F, Palese P. 2013. Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr Opin Virol 3:521-530. http://dx.doi.org/10.1016/j.coviro.2013.07.007.
271. de Alwis R, Williams KL, Schmid MA, Lai CY, Patel B, Smith SA, Crowe JE, Wang WK, Harris E, de Silva AM. 2014. Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera. PLoS Pathog 10:e1004386. http://dx.doi.org/10.1371/journal.ppat.1004386.
272. Kliks SC, Nisalak A, Brandt WE, Wahl L, Burke DS. 1989. Antibody- dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg 40:444 -451.
273. Kliks SC, Nimmanitya S, Nisalak A, Burke DS. 1988. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg 38:411-419.
274. Gromowski GD, Barrett AD. 2007. Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. Virology 366: 349-360. http://dx.doi.org/10.1016/j.virol.2007.05.042.
275. Watanabe K, Hess A, Bloch W, Michel O. 2000. Inhibition of inducible nitric oxide synthase lowers the cochlear damage by lipopolysaccharide in guinea pigs. Free Radic Res 32:363-370. http://dx.doi.org/10.1080/10715760000300361.
276. Guttman M, Cupo A, Julien JP, Sanders RW, Wilson IA, Moore JP, Lee KK. 2015. Antibody potency relates to the ability to recognize the closed, pre-fusion form of HIV Env. Nat Commun 6:6144. http://dx.doi.org/10.1038/ncomms7144.
277. Dowd KA, DeMaso CR, Pierson TC. 2015. Genotypic differences in dengue virus neutralization are explained by a single amino acid mutation that modulates virus breathing. mBio 6:e01559-15. http://dx.doi.org/10.1128/mBio.01559-15.
278. Thullier P, Lafaye P, Megret F, Deubel V, Jouan A, Mazie JC. 1999. A recombinant Fab neutralizes dengue virus in vitro. J Biotechnol 69:183- 190. http://dx.doi.org/10.1016/S0168-1656(99)00037-1.
279. Cockburn JJ, Navarro Sanchez ME, Fretes N, Urvoas A, Staropoli I, Kikuti CM, Coffey LL, Arenzana Seisdedos F, Bedouelle H, Rey FA. 2012. Mechanism of dengue virus broad cross-neutralization by a monoclonal antibody. Structure 20:303-314. http://dx.doi.org/10.1016/j.str.2012.01.001.
280. Burton DR, Ahmed R, Barouch DH, Butera ST, Crotty S, Godzik A, Kaufmann DE, McElrath MJ, Nussenzweig MC, Pulendran B, Scanlan CN, Schief WR, Silvestri G, Streeck H, Walker BD, Walker LM, Ward AB, Wilson IA, Wyatt R. 2012. A blueprint for HIV vaccine discovery. Cell Host Microbe 12:396-407. http://dx.doi.org/10.1016/j.chom.2012.09.008.
281. Diskin R, Scheid JF, Marcovecchio PM, West AP Jr, Klein F, Gao H, Gnanapragasam PN, Abadir A, Seaman MS, Nussenzweig MC, Bjorkman PJ. 2011. Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science 334:1289-1293. http://dx.doi.org/10.1126/science.1213782.
282. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, Wang SK, Ramos A, Chan-Hui PY, Moyle M, Mitcham JL, Hammond PW, Olsen OA, Phung P, Fling S, Wong CH, Phogat S, Wrin T, Simek MD, Protocol G Principal Investigators, Koff WC, Wilson IA, Burton DR, Poignard P. 2011. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477:466-470. http://dx.doi.org/10.1038/nature10373.
283. Pejchal R, Doores KJ, Walker LM, Khayat R, Huang PS, Wang SK, Stanfield RL, Julien JP, Ramos A, Crispin M, Depetris R, Katpally U, Marozsan A, Cupo A, Maloveste S, Liu Y, McBride R, Ito Y, Sanders RW, Ogohara C, Paulson JC, Feizi T, Scanlan CN, Wong CH, Moore JP, Olson WC, Ward AB, Poignard P, Schief WR, Burton DR, Wilson IA. 2011. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 334:1097-1103. http://dx.doi.org/10.1126/science.1213256.
284. Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, Finzi A, Kwon YD, Scheid JF, Shi W, Xu L, Yang Y, Zhu J, Nussenzweig MC, Sodroski J, Shapiro L, Nabel GJ, Mascola JR, Kwong PD. 2010. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329: 811-817. http://dx.doi.org/10.1126/science.1192819.
285. Barba-Spaeth G, Dejnirattisai W, Rouvinski A, Vaney MC, Medits I, Sharma A, Simon-Loriere E, Sakuntabhai A, Cao-Lormeau VM, Haouz A, England P, Stiasny K, Mongkolsapaya J, Heinz FX, Screaton GR, Rey FA. 23 June 2016. Structural basis of potent Zikadengue virus antibody cross-neutralization. Nature http://dx.doi.org/10.1038/nature18938.
286. Halstead SB. 2003. Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 60:421-467. http://dx.doi.org/10.1016/S0065-3527(03)60011-4.
287. Doria-Rose NA, Louder MK, Yang Z, O'Dell S, Nason M, Schmidt SD, McKee K, Seaman MS, Bailer RT, Mascola JR. 2012. HIV-1 neutralization coverage is improved by combining monoclonal antibodies that target independent epitopes. J Virol 86:3393-3397. http://dx.doi.org/10.1128/JVI.06745-11.
288. Goo L, Jalalian-Lechak Z, Richardson BA, Overbaugh J. 2012. A combination of broadly neutralizing HIV-1 monoclonal antibodies targeting distinct epitopes effectively neutralizes variants found in early infection. J Virol 86:10857-10861. http://dx.doi.org/10.1128/JVI.01414-12.
289. Long WS, Seashore MR, Siegel NJ, Bia MJ. 1990. Idiopathic Fanconi syndrome with progressive renal failure: A case report and discussion. Yale J Biol Med 63:15-28.
290. Bouvin-Pley M, Morgand M, Moreau A, Jestin P, Simonnet C, Tran L, Goujard C, Meyer L, Barin F, Braibant M. 2013. Evidence for a con-Tinuous drift of the HIV-1 species towards higher resistance to neutralizing antibodies over the course of the epidemic. PLoS Pathog 9:e1003477. http://dx.doi.org/10.1371/journal.ppat.1003477.
291. Pollara J, Bonsignori M, Moody MA, Liu P, Alam SM, Hwang KK, Gurley TC, Kozink DM, Armand LC, Marshall DJ, Whitesides JF, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Robb ML, O'Connell RJ, Kim JH, Michael NL, Montefiori DC, Tomaras GD, Liao HX, Haynes BF, Ferrari G. 2014. HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities. J Virol 88:7715-7726. http://dx.doi.org/10.1128/JVI.00156-14.
292. Kong R, Louder MK, Wagh K, Bailer RT, deCamp A, Greene K, Gao H, Taft JD, Gazumyan A, Liu C, Nussenzweig MC, Korber B, Montefiori DC, Mascola JR. 2015. Improving neutralization potency and breadth by combining broadly reactiveHIV-1antibodies targeting major neutralization epitopes. J Virol 89:2659-2671. http://dx.doi.org/10.1128/JVI.03136-14.
293. Wagh K, Bhattacharya T, Williamson C, Robles A, Bayne M, Garrity J, Rist M, Rademeyer C, Yoon H, Lapedes A, Gao H, Greene K, Louder MK, Kong R, Karim SA, Burton DR, Barouch DH, Nussenzweig MC, Mascola JR, Morris L, Montefiori DC, Korber B, Seaman MS. 2016. Optimal combinations of broadly neutralizing antibodies for prevention and treatment of HIV-1 clade C infection. PLoS Pathog 12:e1005520. http://dx.doi.org/10.1371/journal.ppat.1005520.
294. Klein F, Gaebler C, Mouquet H, Sather DN, Lehmann C, Scheid JF, Kraft Z, Liu Y, Pietzsch J, Hurley A, Poignard P, Feizi T, Morris L, Walker BD, Fatkenheuer G, Seaman MS, Stamatatos L, Nussenzweig MC. 2012. Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein. J Exp Med 209:1469-1479. http://dx.doi.org/10.1084/jem.20120423.
295. Cheung WC, Beausoleil SA, Zhang X, Sato S, Schieferl SM, Wieler JS, Beaudet JG, Ramenani RK, Popova L, Comb MJ, Rush J, Polakiewicz RD. 2012. A proteomics approach for the identification and cloning of monoclonal antibodies from serum. Nat Biotechnol 30:447-452. http://dx.doi.org/10.1038/nbt.2167.
296. Wine Y, Boutz DR, Lavinder JJ, Miklos AE, Hughes RA, Hoi KH, Jung ST, Horton AP, Murrin EM, Ellington AD, Marcotte EM, Georgiou G. 2013. Molecular deconvolution of the monoclonal antibodies that comprise the polyclonal serum response. Proc Natl Acad Sci U S A 110:2993- 2998. http://dx.doi.org/10.1073/pnas.1213737110.
297. Jardine J, Julien JP, Menis S, Ota T, Kalyuzhniy O, McGuire A, Sok D, Huang PS, MacPherson S, Jones M, Nieusma T, Mathison J, Baker D, Ward AB, Burton DR, Stamatatos L, Nemazee D, Wilson IA, Schief WR. 2013. Rational HIV immunogen design to target specific germline B cell receptors. Science 340:711-716. http://dx.doi.org/10.1126/science.1234150.
298. Bohne-Lang A, von der Lieth CW. 2005. GlyProt: in silico glycosylation of proteins. Nucleic Acids Res 33:W214-W219. http://dx.doi.org/10.1093/nar/gki385.